Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis

• Published in: Value in health 2014, Vol.17 (1), p.109-115
• Main Authors: Bujkiewicz, Sylwia, PhD, Thompson, John R., PhD, Sutton, Alex J., PhD, Cooper, Nicola J., PhD, Harrison, Mark J., PhD, Symmons, Deborah P.M., PhD, Abrams, Keith R., PhD
• Format: Article
• Language: English
• Subjects: Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Assessment; Bayes Theorem; Bayesian analysis; Biological and medical sciences; Clinical outcomes; General aspects; Health; health technology assessment; Humans; Internal Medicine; Mapping; Medical sciences; Medical technology; meta-analysis; Meta-Analysis as Topic; Methodological; Miscellaneous; multiple end points; Planification. Prevention (methods). Intervention. Evaluation; Public health. Hygiene; Public health. Hygiene-occupational medicine; Quality of Life; rheumatoid arthritis; surrogate end points; Surveys and Questionnaires; Technology Assessment, Biomedical; Uncertainty
• ISSN: 1098-3015; 1524-4733
• DOI: 10.1016/j.jval.2013.11.005

Abstract Background In health technology assessment, decisions about reimbursement for new health technologies are largely based on effectiveness estimates. Sometimes, however, the target effectiveness estimates are not readily available. This may be because many alternative instruments measuring these outcomes are being used (and not all always reported) or an extended follow-up time of clinical trials is needed to evaluate long-term end points, leading to the limited data on the target clinical outcome. In the areas of highest priority in health care, decisions are required to be made on a short time scale. Therefore, alternative clinical outcomes, including surrogate end points, are increasingly being considered for use in evidence synthesis as part of economic evaluation. Objective To illustrate the potential effect of reduced uncertainty around the clinical outcome on the utility when estimating it from a multivariate meta-analysis. Methods Bayesian multivariate meta-analysis has been used to synthesize data on correlated outcomes in rheumatoid arthritis and to incorporate external data in the model in the form of informative prior distributions. Estimates of Health Assessment Questionnaire were then mapped onto the health-related quality-of-life measure EuroQol five-dimensional questionnaire, and the effect was compared with mapping the Health Assessment Questionnaire obtained from the univariate approach. Results The use of multivariate meta-analysis can lead to reduced uncertainty around the effectiveness parameter and ultimately uncertainty around the utility. Conclusions By allowing all the relevant data to be incorporated in estimating clinical effectiveness outcomes, multivariate meta-analysis can improve the estimation of health utilities estimated through mapping methods. While reduced uncertainty may have an effect on decisions based on economic evaluation of new health technologies, the use of short-term surrogate end points can allow for early decisions. More research is needed to determine the circumstances under which uncertainty is reduced.